Volumen: 17 # Number : 2
Publication Date : Mayo - Agosto Year: 2013
Authors: Shanley C, Fantl D
Abstract: Brentuximab Vedotin is an antibody-drug conjugate,
with a novel mechanism of action combining a cytotoxic agent with a monoclonal antibody. It shows a safety profile and it demonstrated a high rate of response in patients with relapsed or refractory
anaplastic large cell lymphoma and Hodgkin lymphoma. There are ongoing trials using this drug earlier in these diseases, in combination with other chemotherapy, or as a bridge therapy before autologous or allogeneic bone marrow transplantation.
Key words: brentuximab vedotin, SGN-35, Hodgkin lymphoma, anaplastic large cell lymphoma, antibody-
drug conjugate.
Pages : 169-175
|
